Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.

Détails

ID Serval
serval:BIB_CED5BE78B134
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
Périodique
Methods in molecular biology
Auteur⸱e⸱s
Bassani-Sternberg M.
ISSN
1940-6029 (Electronic)
ISSN-L
1064-3745
Statut éditorial
Publié
Date de publication
2018
Peer-reviewed
Oui
Volume
1719
Pages
209-221
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Recent data indicate that endogenous mutated cancer proteins can be processed and presented as HLA binding peptides, leading to their recognition in vivo as "non-self." Targeting such neoantigens would enable immune cells to distinguish between normal and cancerous cells, avoiding the risk of autoimmunity. So far, discovery of such neoantigens relies mainly on prediction-based interrogation of the "mutanome" using genomic information as input, followed by highly laborious and time-consuming T cell screening assays. Currently, mass spectrometry is the only unbiased methodology to comprehensively interrogate the naturally presented repertoire of HLA binding peptides, including peptides derived from tumor-associated antigens and post-translational modified peptides. This chapter describes a detailed protocol for in-depth and accurate mass spectrometry based immunopeptidomics, enabling the direct identification of tissue-derived neoantigens extracted from human tumors.
Mots-clé
Antigens, Neoplasm/analysis, Antigens, Neoplasm/immunology, Antigens, Neoplasm/metabolism, Chromatography, Affinity/methods, Histocompatibility Antigens Class I/analysis, Histocompatibility Antigens Class I/immunology, Histocompatibility Antigens Class I/metabolism, Histocompatibility Antigens Class II/analysis, Histocompatibility Antigens Class II/immunology, Histocompatibility Antigens Class II/metabolism, Humans, Mass Spectrometry/methods, Neoplasms/immunology, Neoplasms/metabolism, Peptide Fragments/analysis, Peptide Fragments/immunology, Peptide Fragments/metabolism, Cancer immunotherapy, HLA binding peptides, Immunoaffinity purification, Immunopeptidomics, Mass spectrometry, Neoantigens
Pubmed
Création de la notice
08/03/2018 17:36
Dernière modification de la notice
20/08/2019 15:49
Données d'usage